CALC Stock Analysis: Buy, Sell, or Hold?
CALC - CalciMedica, Inc. Common Stock
$0.60
-0.21 (-25.64%)
▼
5d:
-30.38%
30d:
-5.02%
90d:
-3.77%
WAIT
LOW Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When CALC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CALC is down 30.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CALC is down 30.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CALC is currently trading at $0.60, which is considered oversold relative to its 30-day fair value range of $0.68 to $0.92.
Technical Outlook: Technically, CALC is in a uptrend. Immediate support is located at $0.54, while resistance sits at $1.01. Short-term momentum is weak, with the stock down 25.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.33 (+1630.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CALC is in a uptrend. Immediate support is located at $0.54, while resistance sits at $1.01. Short-term momentum is weak, with the stock down 25.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.33 (+1630.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.68 -
$0.92
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-25.6%)
- BULLISH: Trading 1630.0% below Wall St target ($10.33)
- WARNING: Recommendation downgraded due to -30.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.68 -
$0.92
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.54
Resistance Level
$1.02
Current Trend
Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.31
Wall Street Target
$10.33
(+1630.0%)
Share & Embed Analysis
Last updated: June 25, 2026 12:41 AM ET
Data refreshes hourly during market hours. Next update: 1:41 AM
Data refreshes hourly during market hours. Next update: 1:41 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CALC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 57 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 58 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
